Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
PP-PF-OTH-GB-0057 | February 2024

Welcome to BayerPRO

Cardiovascular
Nephrology
Oncology
Women's Health
Latest resources
View more
mCRC Resources
STIVARGA® (regorafenib)
PP-STI-GB-0199, February 2024
NUBEQA®▼ (darolutamide) Resources
PP-NUB-GB-1312, February 2024
HCC Resources
Nexavar® (sorafenib) | Stivarga® (regorafenib)
PP-NEX-GB-0215, February 2024
Patient case study: The forgetful pill taker
Discussion who wants to find a contraceptive method that will suit her busy student lifestyle.
PP-PF-WHC-IUS-GB-0022, February 2024
Events & webinars
View more
Kerendia®▼ (finerenone) Short Videos
PP-KER-GB-0566, March 2024
Chronic Kidney Disease Bitesize Videos
Kerendia®▼ (finerenone)​
PP-KER-GB-0565, February 2024
Common questions in the treatment of VTE
Dr Mari Thomas talks about the treatment of VTE in a series of short videos
RP-XAR-GB-5302, February 2024
Management of VTE in primary care
Professor Ahmet Fuat talks about the role of primary care in the management of VTE
RP-XAR-GB-5304, February 2024
Learning Zone
View more
Module 4:
Motivational Interviewing
RP-XAR-GB-5165, February 2024
Module 3
Motivational Interviewing CPD accredited course
RP-XAR-GB-5164, February 2024
Module 2:
Motivational Interviewing CPD accredited course
RP-XAR-GB-5163, February 2024
Module 1:
Motivational Interviewing CPD accredited course
RP-XAR-GB-5162, February 2024
Podcasts
View more
Current treatment landscape and the future for treating mCRC
Stivarga® (regorafenib)
PP-STI-GB-0201, February 2024
Episode 3
The Practicalities of Treatment — Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0464, February 2024
Episode 1
Why treat with Xofigo®▼ (radium-223 dichloride)?
PP-XOF-GB-0462, February 2024
Episode 2
Optimising patient identification and referral — Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0463, February 2024
Products
View more
Stivarga® (regorafenib)
In mCRC
PP-STI-GB-0204, February 2024
Nexavar® (sorafenib) & Stivarga® (regorafenib)
In HCC
PP-NEX-GB-0211, February 2024
Xofigo®▼ (radium-223 dichloride)
In mCRPC
PP-XOF-GB-0460, February 2024
Xarelto®
Protect what matters most for your eligible cardiovascular patients
PP-XAR-GB-3601, February 2024
Register with BayerPRO

To access additional resources, personalise your experience and keep up to date via electronic communications from Bayer.

 

Areas of Interest
Cardiovascular
Women's Health
Nephrology
Oncology
Respiratory
Reporting adverse events and quality complaints

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc.

If you want to report an adverse event or quality complaint, reports can be directed to Tel: 0118 206 3500 or Email: pvuk@bayer.com. 

Further information is available on the "contact" tab at www.bayer.co.uk.

Register with BayerPRO

To access additional resources, personalise your experience and keep up to date via electronic communications from Bayer.

Register | Login

BayerPRO is developed and fully funded by Bayer plc.​ ​